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ity or alteration of structure of materials. In the preferred 
embodiment, the method includes applying the ultrasound in 
combination with devices for monitoring and/or implement-
ing feedback controls. 
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METHOD OF APPLYING ACOUSTIC 
ENERGY EFFECTIVE TO ALTER 
TRANSPORT OR CELL VIABILITY 
2 
National Counce! on Radiation Protection and Measurements 
(Bethesda, Md. 1992)). Under a very different conditions 
(that is, a spectrum of lower frequencies and high intensity), 
routine lithotripsy procedures use focused acoustic energy to 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This is a continuation of U.S. Ser. No. 091229,226, filed 
Jan. 12, 1999 now U.S. Pat. No. 7,273,458 entitled "Assess-
ment and Control of Acoustic Tissue Effects" by Mark Praus-
nitz, Jin Liu, and Thomas N. Lewis; which claims priority to 
U.S. Provisional Applications Ser. No. 60/071,240 filed Jan. 
12, 1998, and Ser. No. 60/085,304, filed May 13, 1998. 
5 noninvasively shatter kidney stones so the fragments can be 
excreted by the body without surgery (Coleman and Saun-
ders, Ultrasonics 31: 7 5-89 (1993) ). Kidney stone destruction 
by lithotripsy is believed to be mediated by cavitation. 
Tachibana, et al., Cancer Lett. 78(1-3):177-181 (1994); Can-
lO cer Lett. 72(3):195-199 (1993) have reported on the use of 
topically applied ultrasound in combination with a photosen-
sitizer to kill tumor cells and on the combination of topically 
applied ultrasound in combination with gas containing micro-
BACKGROUND OF THE INVENTION 
The present invention is in the field of controlled applica-
tion of acoustic energy to tissue and cells, and more particu-
larly to assessment and control of acoustic energy as a means 
15 spheres to enhance lysis of thrombi, in Circulation 92(5): 
1148-1150 (1995) and U.S. Pat. No. 5,315,998 to Tachibana, 
et al. 
of enhancing the permeability of cells and tissue for admin- 20 
istration of chemical or biological agents. 
Ultrasound-mediated administration of drugs, genes, and 
other therapeutic compounds into and across cells and tissues 
has shown significant potential in target drug delivery. For 
example, studies have shown that appropriately applied ultra- 25 
sound can reversibly permeability viable cells so that exog-
enous material can enter those cells without killing them. 
Ultrasound-enhanced delivery to cells has been demonstrated 
in vitro by uptake of extracellular fluid (Williams, J. Cell Sci. 
12: 875-85 (1973)); drugs (Saad and Hahn, Ultrasound Med. 30 
Biol. 18: 715-23 (1992)); and DNA into both cells (Fechhe-
imer, et al., Proc. Natl. Acad. Sci. USA 84: 8463-67 (1987); 
Kim, et al., Human Gene Ther. 7; 1339-46 (1996); Bao, et al., 
Ultrasound Med. Biol. 23: 953-59 (1997); Wyber, et al., 
Pharm. Res. 14: 750-56 (1997)) and plant tissues (Zhang, et 35 
al., Bio/Technology 9: 996-97 (1991)). 
Similarly, acoustic effects oflithotripters have been shown 
to permeability cell membranes. (Holmes, et al.,J. Ural. 147: 
733-37 (1992); Gambihler, et al., J. Membr. Biol. 141: 267-75 
( 1994) ). Ultrasound also has been shown to increase transport 40 
of small drugs and proteins across skin, which is ofinterest for 
topical and systemic transdermal drug delivery (Kost and 
Langer, "Ultrasound-mediated transdermal drug delivery" in 
Tropical Drug Bioavailability, Bioequiavalence, and Pen-
etration (Shan & Maibach (eds.)) pp. 91-104 (Plenum Press, 45 
New York 1993); Mitragoti, et al., Pharm. Res. 13: 411-20 
(1996); (Mitragotri, et al., Science 269: 850-53 (1995); Praus-
nitz, "Transdermal delivery of proteins: recent advances by 
modification of skin's barrier properties" in Therapeutic Pro-
tein and Peptide Formulation and Delivery (Shahrokh, et al., 50 
eds.) pp. 124-53 (American Chemical Society, Washington, 
D.C. 1997). 
Ultrasound has been a well established diagnostic and 
therapeutic tool in medicine for decades (Stewart and Strat-
meyer, eds., An Overview of Ultrasound: Theory, Measure- 55 
ment, Medical Applications, and Biological Effects (FDA 
82-8190) (U.S. Department of Health and Human Services, 
Rockville, Md. 1983); Suslick, ed., Ultrasound: Its Chemi-
cal, Physical, and Biological Effects (VCH, Deerfield Beach, 
Fla. 1988)). Ultrasound imaging is widely used at high fre- 60 
quency and low intensity conditions, which are believed to 
cause no or minimal effects on cells (Barnett, et al., Ultra-
sound Med. Biol. 20: 205-18 (1994)). Ultrasound also is used 
therapeutically at somewhat greater intensities to heat tissues 
for physical therapy and other hyperthermia treatments (Ex- 65 
posure Criteria for Medical Diagnostic Ultrasound: I. Crite-
ria Based on Thermal Mechanisms (NCRP Report No. 113), 
Acoustic cavitation involves the creation and oscillation of 
gas bubbles in a liquid (Leighton, The Acoustic Bubble (Aca-
demic Press, London (1994)). During the low-pressure por-
tion of an ultrasound wave, dissolved gas and vaporized liq-
uid can form gas bubbles. These bubbles then shrink and grow 
in size, oscillating in response to the subsequent high- and 
low-pressure portions of the ultrasound wave, a process 
referred to as stable cavitation. Transient cavitation occurs at 
greater acoustic pressures, where bubbles violently implode 
after a few cycles. This implosion can have a number of 
effects, including transiently raising the local temperature by 
hundreds of degrees Celsius and the local pressure by hun-
dreds of atmospheres, emitting light by a poorly-understood 
phenomenon called sonoluminescence, creating short-lived 
free radicals, and launching a high-velocity liquid microjet. 
Cavitation also is believed to be responsible for ultrasonic 
permeabilization of cells and tissues of interest for pharma-
ceutical applications (Wyber, et al., Pharm. Res. 14: 750-56 
(1997); Mitragotri, et al., Pharm. Res. 13: 411-20 (1996); 
Barnett, et al,. Ultrasound Med. Biol. 20: 205-18 (1994)). 
Nonetheless, the effects of ultrasound parameters on cavita-
tion and cell membrane permeabilization are not sufficiently 
understood for development and optimization of acoustic 
techniques in, for example, controlled drug delivery. 
It is therefore an object of this invention to provide quan-
titative assessment and control of acoustic tissue effects. 
It is another object of this invention to provide means for 
enhancing the controlled transportation of molecules into or 
across cell or tissue barriers. 
It is still another object ofthis invention to provide means 
for reversibly or irreversibly altering cell or tissue permeabil-
ity, thereby regulating transport or cell or tissue properties 
such as viability or structure. 
SUMMARY OF THE INVENTION 
A method for reversibly, or irreversibly, altering the per-
meability of cells, tissues or other biological barriers, to mol-
ecules to be transported into or through these materials, 
through the application of acoustic energy, is enhanced by 
applying the ultrasound in combination with means for moni-
toring and/or implementing feedback controls. The acoustic 
energy is applied directly or indirectly to the cells or tissue 
whose permeability is to be altered, at a frequency and inten-
sity appropriate to alter the permeability (which includes 
diffusivity) to achieve the desired effect, such as the transport 
of endogenous or exogenous molecules and/or fluid, for drug 
delivery, measurement of analyte, removal of fluid, alteration 
of cell or tissue viability or alteration of structure of materials 
such as kidney, or gall bladder stones. 
US 7,972,286 B2 
3 
In the preferred embodiment, the method includes measur-
ing the strength of the acoustic field applied to the cell or 
tissue at the applied frequency or other frequencies, and using 
the acoustic measurement to modify continued or subsequent 
application of acoustic energy to the cell or tissue. In another 
preferred embodiment, the method further includes simulta-
neously, previously, or subsequently exposing the cell or tis-
sue to the chemical or biological agent to be transported into 
or across the cell or tissue. In another preferred application, 
the method includes removing biological fluid or molecules 10 
from the cells or tissue simultaneously, previously or subse-
quently to the application of acoustic energy and, optionally, 
assaying the biological fluid or molecules. 
In a preferred embodiment, the acoustic energy is applied 
15 
at a frequency between about 1 kHz and 20 MHz, and at a 
peak positive pressure up to 100 atmospheres. The acoustic 
energy can be applied directly to the tissue or cells where the 
effect is desired. Alternatively, the acoustic energy can be 
applied at a site at a distance from the transducer, under 20 
conditions designed to result in a desired effect at the distant 
site. Ultrasound can be applied using non-invasive means (for 
example, by transdermal application), minimally invasive 
means (for example, using a catheter), or during surgery or 
other invasive procedures. The acoustic energy can be applied 25 
alone, or in combination with therapeutic or diagnostic 
agents. 
The method can be used in a variety of applications, includ-
ing drug delivery including gene therapy, administration of 
vaccines, and administration of targeted therapeutic or diag- 30 
nostic agents, detection and/or quantization of analyte, and 
destruction of tissue such as cancers, fatty tissue or materials 
such as kidney or gall bladder stones. 
4 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
Acoustic energy can be used to cause chemical or biologi-
cal agents to be transported into and/or across biological 
barriers, for example, in cells or tissues. Characterizing the 
dependence of cell membrane permeabilization on acoustic 
energy conditions is, however, essential to rationally design-
ing acoustic energy protocols for pharmaceutical and other 
applications. Accordingly, methods are provided herein to 
use the quantitative dependence of cell membrane pearme-
abilization on various acoustic parameters to enhance the 
transport of chemical or biological agents to be transported 
into and/or across biological barriers in cells or tissue, for 
example, to enhance delivery of drugs to cells in a specific 
tissue or to increase uptake of compounds which cross cell 
membranes poorly. 
I. Acoustic Energy 
As used herein, the term "acoustic energy" means any form 
of pressure wave, whether audible or inaudible. The fre-
quency of the acoustic energy can be a single frequency or a 
combination of frequencies. The range of useful frequencies 
preferably is between about 1 Hz and 100 MHz, and more 
preferably is between about 1 kHz and 10 MHz, and most 
preferably between about 15 kHz and 2 MHz. The waveform 
of the acoustic energy can be of any shape, including a sin-
ewave or a combination of sinewaves. The pressure of the 
acoustic energy can be up to a few hundred atmospheres, and 
preferably is applied at a peak positive pressure of up to 100 
atmospheres. The optimal pressure is a function of acoustic 
frequency and other parameters described below. The acous-
tic energy can be applied continuously or intermittently. 
Acoustic energy can be used to enhance transports by a 
number of different mechanisms, which broadly fall into two 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. la and lb are graphs of incident ultrasonic pressure 
(la) and subharmonic pressure (lb) versus percent mem-
brane permeabilization of a suspension of bovine red blood 
cells exposed to continuous ultrasound for 10 sec. at 24 kHz. 
35 classes. In the first class, acoustic energy directly or indirectly 
(e.g. via cavitation) provides a driving force for transport. In 
the second class, acoustic energy increases the permeability 
of the biological barrier, either reversibly, partially reversibly, 
or irreversibly. These two mechanisms can be used indepen-
FIG. 2 is a graph of ultrasound frequency versus pressure, 
which illustrates a representative acoustic spectrum mea-
sured during an ultrasound exposure at f=24 kHz, which 
caused extensive cavitation. 
40 dently or in combination. In the preferred embodiment, both 
mechanisms are used simultaneously. 
FIG. 3 is a graph of ultrasound exposure time verses per- 45 
cent membrane permeabilization for red blood cells exposed 
to continuous ultrasound at 24 kHz for different amounts of 
time at incident pressures of0.89 atm. ( + ), 2.7 atm. (•),and 
8.9 atm. ( ... ). 
FIG. 4 is a graph of length of time of an ultrasound pulse 50 
versus percent membrane permeabilization of cells for pulses 
applied at a duty cycle of 10% at incident pressures of 0.89 
atm. (+), 2.7 atm. (•),and 8.9 atm. ( ... ). 
FIG. 5 is graph ofultrasound duty cycle(%) versus percent 
membrane permeabilization at an incident pressure of 2.7 55 
atm., for a total "on" time of 10 sec. at a pulse length of0.1 
sec.(+) or 1 sec. (•). 
FIG. 6 is a graph of the acoustic parameter i:-Pf72 versus 
percent membrane permeabilization, using the data from 
FIGS. 1-5. 
FIG. 7 is a graph showing average uptake of calcein mol-
ecules per exposed cell ( o) and fraction of viable cells (•) 
relative to unexposed control, each is a function of peak 
incident pressure for 20pulses at0.1 sec. and 10% duty cycle. 
60 
In the first class, where acoustic energy directly or indi-
rectly provides a driving force for transport, both cavitational 
and non-cavitational mechanisms can be involved. Under 
appropriate low frequency, high pressure conditions, acoustic 
energy can cause cavitation, which is the creation of gas 
cavities, or bubbles, which oscillate stably in the acoustic 
field and/or collapse, as can be seen during transient or iner-
tial cavitation. The appropriate conditions will depend on the 
temperature, gas content, acoustic conditions, viscosity and 
the other properties of the system and acoustic field. Cavita-
tional and non-cavitational acoustic energy also can provide 
convective or hydrodynamic driving forces for transport, 
including acoustic streaming, microstreaming, and local, 
high-velocity jets caused by transient cavitation. Also, chemi-
cal and other changes caused by acoustic energy can alter the 
local environment, thereby changing local chemical poten-
tials, which can alter the chemical potential driving force for 
net transport by diffusion. 
In the second class, where acoustic energy increases the 
permeability of the biological barrier, either reversibly, par-
tially reversibly, or involved. For example, increased pearme-
ability can be achieved by heating, thereby increasing diffu-
sivity of the molecules. Increased permeability can also be 
FIG. 8 is a graph showing average uptake of calcein mol-
ecules per cell as a function of time which calcein was added 
to the cell suspension after exposure. 
65 achieved by altering physical structures within biological 
barriers, such as re-organizing the structure oflipid bilayers, 
intercellular junctions, and extracellular matrix. These physi-
US 7,972,286 B2 
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cal effects can be caused by one or more factors, including 
bulk heating, cavitation, acoustic streaming, microstreaming, 
high-velocity jets, mechanical interactions, local heating by 
cavitation, local pressure increases by cavitation, and chemi-
cal effects due to creation of free radicals, or stimulation of 
other chemical reactions. 
Preselected Conditions 
Acoustic enhancement can be used to alter transport ( typi-
cally by altering permeability to the molecules to be trans-
ported to the material through which they are to pass) or 10 
structural integrity of biological materials. The parameters 
can be selected prior to applications, based on previous stud-
ies or empirical results. In a preferred method, however, feed-
back is obtained so that the acoustic enhancement is modified 
after the initial application as needed to optimize results as 15 
treatment progresses. 
Acoustic Measurement Feedback 
Feedback can involve measurement of one or more vari-
ables. Variables include subharmonic pressure, acoustic 
parameters, temperature, amount or rate of transport of mo!- 20 
ecules, extent of cavitation, and degree of permeabilization. 
In one embodiment, the acoustic energy or pressure is mea-
sured at one or more frequencies other than the frequency or 
frequencies at which the acoustic energy is applied. For 
example, the acoustic energy or pressure is measured at a 25 
frequency or frequencies corresponding to integer multiples 
of one-half or one-fourth of the frequency applied. 
As described in Example 1 below, membrane pearmeabi-
lization is mediated by cavitation, so that subharmonic pres-
sure can be used as a noninvasive way to determine the degree 30 
of permeabilization resulting from exposure to acoustic 
energy. In addition, permaeabiliziation caused by ultrasound 
should be well predicated by the acoustic parameter i:·P1w 
which characterizes the total cavitational exposure by 
accounting for both the strength of the f/2 cavitation signal 35 
and the time over which it acts. 
In a preferred embodiment, the method of enhancing trans-
port of chemical or biological agents across or into a biologi-
cal barrier includes the following steps: 
6 
cines. Representative polynucleic acid molecules include 
antisense, aptamers, ribozymes, and genes, plasmids, and 
viral vectors. Representative synthetic organic or inorganic 
drugs include anti-inflammatories, antivirals, antifungals, 
antibiotics and local anesthetics. As used herein, the agents 
can be molecules or aggregates or other multi-molecular 
structures, including for example, virus particles or cells, 
liposomes or other lipid vesicles or emulsions, or particles 
including nano or microspheres or capsules. For direct appli-
cation, the drug will typically be administered in an appro-
priate pharmaceutically acceptable carrier having an acoustic 
impedance similar to water, such as an aqueous gel, ointment, 
lotion, or suspension. Alternatively, a transdermal patch can 
be used as a carrier. 
A variety of analytes are routinely measured in the body 
fluids such as blood, interstitial fluid, lymph, intracellular 
fluid or cerebral spinal fluid. Examples of typical analyzes 
that cain be measured include blood sugar (glucoese ), cho-
lesterol, bilirubin, creatinine, vitamin Kor other clotting fac-
tors, uric acid, carcinoembryonic antigen or other tumor anti-
gens, and various reproductive hormones such as those 
associated with ovulation or pregnancy. Other analytes that 
can be measured include alcohol and drugs. 
III. Applications 
The methods described herein can be used to enhance 
transport of agents into or across a variety of biological bar-
riers. Representative barriers include mammalian and non-
mamminalian tissues, including skin, tumor, muscle, lung, 
brain, heart, blood vessel, bone, cartilage, and internal organs. 
The tissue or cell can be a part of a living organism, obtained 
from living organism, or intended to become part of a living 
organism, for example, for use in tissue regeneration or tissue 
engineering, in the form of tissue or dissociated cells. Other 
representative biological barriers include externally acces-
sible barriers, such as skin, the eye (cornea) conjunctiva, 
sclera), and the mucosa of the nose, mouth, rectum and 
vagina, as well as internal barriers, such as the gastrointestinal 
tract and pulmonary mucosa, blood and lymphatic vessel 
walls (including the blood-brain barrier), internal organs, 
(a) applying acoustic energy to the biological barrier, for 
example, the cells or tissue, at one or more frequencies; 
(b) measuring the strength of the acoustic field applied to 
the cells or tissue at the applied frequency or other frequen-
cies; and 
40 tumors, and bones. The barrier can be in the form of intercel-
lular junctions, extracellular matrices, or cell membranes for 
introduction of material into or out of the interior of a cell or 
cells. In one preferred embodiment, the biological barrier is 
human skin. 
( c) using the acoustic measurement obtained in step (b) to 45 
modify continued or subsequent application of acoustic 
energy to the cells or tissue. 
For example, in a preferred embodiment, a device applies 
ultrasound to a tissue and the f/2 signal is measured to assess 
the degree to which the tissue was permeability. This infor- 50 
mation can be used to estimate the amount of drug delivered. 
Measurement of the f/2 signal provides a method for real-time 
feedback so that the ultrasound exposure based on pre-pro-
grammed or user-selected drug delivery profiles can be opti-
mized. The technology required for both generating acoustic 55 
energy and "listening" to f/2 signals is known in the art, 
relatively inexpensive when mass produced, and is readily 
miniaturizable. 
II. Chemical or Biological Agents 
The methods described herein can used to enhance trans- 60 
port of essentially any endogenous chemical or biological 
agent for therapeutic, diagnostic, or prophyiactic purposes 
into or across biological barriers. Useful agents include pep-
tides, proteins, sugars, polysaccharides, nucleotides, poly-
nucleotide molecules, and other synthetic organic or inor- 65 
ganic compounds. Representative proteins and peptides 
include hormones such as insulin, growth factors, and vac-
As used herein, the phrase "bioiogical barrier" encom-
passes cell membranes, tissue, tissue membranes, intercellu-
lar membranes, and biological materials such as kidney 
stones. It is understood that the technology can be applied 
directly or indirectly to these materials. 
The methods of enhancing transport can be performed with 
acoustic energy parameters that are preselected and/or that 
are adjusted based on acoustical measurement feedback. 
Acoustic enhancement can preceed, occur simultaneously, 
or follow treatment with other agents which may be used in 
combination with the ultrasound to affect transport. For 
example, chemical enhancers that increase solubility of the 
materials to be transported, permeability enhancers, or even 
other driving forces such as mechanical or physical forces 
(vacuum, pressure, electrical forces) may be used with the 
ultrasound. 
Acoustic enhancement which is administered to enhance 
transport out of cells or tissues, for example, for measurement 
of analyte, is administered in an amount which is effective, 
alone or in combination with other transport enhancers, to 
extract analyte for detection or quantitation. Acoustic 
enhancement which is administered to enhance transport of 
fluid out of tissue or cells is administered in an amount which 
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is effective, alone or in combination with other transport 
enhancers, to extract fluid, for example, as required to reduce 
swelling or shrink tissue for easier extraction using other 
methods or to facilitate breakdown of structural integrity. 
Acoustic enhancement which is administered to degrade 
structural integrity or kill cells is administered in an amount 
effective to dissociate cells or tissue or other material such as 
a kidney or gall bladder stone (usually formed of calcium 
and/or lipid materials) or to irreversibly alter the cell perme-
ability so that the cells become unviable. 
Acoustic enhancement which is administered to enhance 
transport is administered directly or indirectly as required to 
alter the rate or extent of transport. Enhancement may be 
measured by an increase in transport, for example, using a 
marker such as blood levels following transdermal delivery, 
or through an end result, for example, following introduction 
of genes into tissue, by expression of the product encoded by 
the genes. 
The transport methods described herein can be used to alter 
transport as part of a variety of procedures. Acoustic energy 
can be focused on the target tissue, using an invasive, mini-
mally-invasive, or non-invasive method, to increase transport 
locally without significantly affecting other tissues. In a pre-
ferred embodiment, acoustic energy is applied non-invasively 
using one or more transducers to focus energy onto the body 
surface or at a site deeper in the body. In another preferred 
embodiment, a minimally-invasive method is used, in which, 
8 
Experimental Methods 
Bovine red blood cells were exposed to ultrasound at 24 
kHz over a range of controlled conditions. The degree of 
membrane permeabilization was measured by release of 
hemoglobin and was determined as a function of ultrasound 
parameters and measured acoustic signals. 
Sample Preparation 
Freshly drawn bovine blood with Alsevers anticoagulant 
(Rockland, Gilbertsville, Pa.) was stored at 4 ° C. for up to 10 
10 days. Red blood cells were collected by centrifugation (GS-
15R, Beckman Instruments, Palo Alto, Calif.; 400 g, lOmin., 
4° C.); washed three times with phoshate-buffered saline 
(PBS; pH 7.4; Sigma, St. Louis, Mo.); and then suspended in 
15 
PBS at a red blood cell concentration of 10% by volume. The 
cell suspension was stored on ice and gently mixed on a 
nutator (Innovative Medical Systems, Ivyland, Pa.) immedi-
ately before use in an experiment. 
The cell suspension was added to a sample tube, which was 
20 prepared by cutting a 15 ml polypropylene centrifuge tube 
(VWR, Suwanee, Ga.) at the 4 ml line. After the sample tube 
was filled with 4 ml of the cell suspension, a rubber stopper 
(VWR) was carefully inserted into the tube to the 3 ml line, 
thereby spilling out about 1 ml of the suspension. This pro-
25 cedure was used so that the tube could be sealed without 
entrapping air bubbles. A hydrophlone (Baylor School of 
Medicine, Houston, Tex.) also was inserted through a small 
hole in the center of the rubber stopper and position at the 
for example one or more transducers are attached to a lapro-
scopic device for the treatment of tissue accessible from the 
gastrointestinal tract in, for example, the treatment of colon 
cancer, or to a catheter for the treatment of tissue accessible 
30 from the vasculature in, for example, the treatment of athero-
sclerosics or restinosis. An invasive approach can be used to 
treat any tissue. For example, the acoustic energy can be 
applied in conjunction with another invasive procedure, such 
center of the sample volume. 
Exposure to Ultrasound 
The ultrasound exposure chamber consisted of a cylindri-
cal piezoelectric transducer (lead ziconate titanate, 5 cm OD, 
4.5 cm ID, 2.5 cm length; Channel Industries, Santa Barbara, 
Calif.) sandwiched between two 10 cm lengths of 1.5 inch as surgery. 
In a preferred embodiment, transdermal delivery of a drug, 
such as insulin, is enhanced by the use of acoustic energy to 
cause compounds to be transported into and/or across the 
skin. In another preferred embodiment, a biological material, 
such as glucose, is transported out of the body through/from 
the skin using a method facilitated by acoustic energy, 
In a similar preferred embodiment, a drug is delivered from 
outside the body to its interior, or a molecule from inside the 
body to the exterior, across barriers other than skin, such as 
the epithelia of the eye, nose, mouth, rectum, or vagina, using 
a method facilitated by acoustic energy. 
In another preferred embodiment, acoustic energy is used 
to enhance targeted drug delivery by selectively increasing 
transport of a drug into a target tissue, such as the brain or a 
tumor. Some tissues, such as tumors, are particularly resistant 
to transport. Accordingly, acoustic energy can significantly 
enhance delivery of drug to those tissues. 
35 Schedule 40 poly( vinyl chloride) (PVC) pipe. The bottom of 
the chamber was sealed on a clear polycarbonate base 
(LEXAN ™, General Electric, Mt. Vernon, Ind.). The cham-
ber was filled with water which was filtered/deionized (Typle 
III; U.S. Filter, Roswell, Ga.) and degassed using a vacuum 
40 chamber (Nalgene, Rochester, N.Y.; pump: 2107VA20A, 
Thomas, Sheboygan, Wis.). 
The sample tube was placed in the water bath within the 
ultrasound exposure chamber, positioned at the axial and 
radial center of the transducer, and exposed to low-frequency 
45 (24 kHz) ultrasound at room temperature (22±2° C.). A func-
tion generator (DS345, Stanford Research System, Sunny-
vale, Calif.) was programmed to provide a sinewave of 
selected voltage, duty cycle, burst length, and total exposure 
time. The output was fed to an amplifier (Macro-tech 2400, 
50 Crown, Elkart, Ind.) the signal of which went through a 
matching transformer (MT-56R, Krohn-Hite, Avon, Mass.) to 
drive the transducer. 
Other compounds, particularly larger marcomolecules, are 
especially difficult to drive into cells or tissue of any type. The 
transport of these compounds also can be enhanced by appli-
cation of acoustic energy. For example, in gene therapy, a 
target tissue could be treated with acoustic energy to facilitate 55 
delivery of DNA into cells. 
Measurement of Ultrasound Pressure 
To monitor the ultrasound exposure, the voltage applied to 
the transducer was measured with an oscilloscope (54603B. 
Hewlett Packard, Santa Clara, Calif.). This voltage was used 
to estimate the incident ultrasound pressure, as described 
below. In addition, the signal from the hydrophone in the 
sample tube was fed to the oscilloscope and a spectrum ana-
The compositions and methods of preparation and use 
thereof described herein are further described by the follow-
ing non-limiting examples. 
EXAMPLE 1 
Exposure of Bovine Red Blood Cells to Ultrasound 
The dependence of cell membrane permeabilization on 
ultrasound parameters was determined and the acoustic sig-
nals which correlate with observed membrane permeabiliza-
tion were identified. 
60 lyzer (SR760, Stanford Research Systems), which was used 
to determine the amplitude of different acoustic signals 
shown in FIG. 2 and Table 1. Higher harmonics of f(e.g. 
2f=48 kHz) are seen in FIG. 2, due to cavitation and apparatus 
resonance. Cavitation also generates other signals, including 
65 the subharmonic (f/2=12 kHz) and its ultraharmonics (e.g. 
3f/2=36 kHz) and an elevated broadband "noise" level (e.g., 
bl, b2). The acoustic spectrummeasureed during exposure of 
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cells to ultrasound provided information about cavitation and 
its effects on membrane permeability, as described below. 
The strength of ultrasound is reported as its incident pres-
sure. The incident pressure is defined as the pressure level that 
would exist in the absence of cavitation, which is primarily at 
the driving frequency (i.e. 24 kHz). The incident pressure is 
important because one of the effects of cavitation is to shift 
acoustic energy to frequencies other than the driving fre-
quency, as shown FIG. 2. Incident pressure is the most useful 
means to characterize ultrasound, because it is independent of 10 
apparatus geometry and represents the total relevant acoustic 
input. For propagating wave fields created by a planar trans-
ducer at high frequency, ultrasound strength is often reported 
as an intensity (e.g., in units W/cm2 ). For ultrasonic irradia-
15 
tion of a surface such as skin with a planar transducer, this 
approach seems appropriate (Kost and Langer, "Ultrasound-
mediated transdermal drug delivery" in Tropical Drug Bio-
availability, Bioequivalence, and Penetration (Shah & Mai-
bach, eds.) pp. 91-104 (Plenum Press, New York 1993)). In 
20 
this experiment however, a radially-symmetric standing 
wave-like field is generated because of the cylindrical geom-
etry of the transducer and because of the use oflow frequency 
ultrasound with a wavelength comparable to the apparatus 
diameter, which field makes acoustic intesity extremely dif-
25 
ficult to determine. Alternatively, the reported pressure can be 
directly measured with a hydrophone at the driving fre-
quency. While this approach is useful at low acoustic levels 
where the measured pressure has the same value as the inci-
dent pressure, at higher intensities where cavitation occurs, 
30 
acoustic energy is shifted to a spectrum of other frequencies, 
as shown in FIG. 2. Thus, the pressure measured at the driving 
frequency accounts for only a portion of the ultrasound expo-
sure applied to the cells. 
10 
negligible, the measured heating rates described above can be 
used to determine the power output of the transducer with the 
equation 
(2) 
where W is power, mwater is the mass of water in the water 
beth (0.3 kg), CPwater is the heat capacity of water (4.18 J/g 0 
C.), and dT/dt is the change of temperature with respect to 
time (e.g., 0.17° C./min. at 2.2 atm.). For example, this equa-
tion yields 3.4 Wat 2.2 atm and 15.1Wat4.5 atm. using the 
heating rates given provided above. This type of calorimetric 
method is commonly used to estimate ultrasonic power 
(Kimura, et al., Ultrasonics Sonochem. 3: S157-S161 (1996). 
A second method to determine the power of ultrasound 
exposures was to measure the electrical power supplied to the 
transducer. The values determined by the two methods should 
be equal ifthere is complete conversion of electrical power to 
acoustic power by the transducer (i.e., 100% efficiency). The 
voltage across the transducer was measured directly with an 
oscilloscope (model 2430A, Tektronics, Beaverton, Oreg.) 
and the current was measured using a current transformer 
(Model 2100, Pearson Electronics, Palo Alto, Calif.) and fed 
to thle oscilloscope. The average power was calculated as the 
average of the product of the current and voltage signals and 
yielded the following relationship 
w~o.00010·V2 (r2~1.00) (3) 
where power (W) has units of watts and peak-to-peak voltage 
(V) has units of volts. Combination of Equations 1 and 3 
yields the following equation which relates power to incident 
pressure for the experimental apparatus used herein: 
w~u·F2 (4) 
where power (W) has units of watts and incident pressure (P) 
has units of atmospheres. This equation indicates the power is 
6.3 Wat 2.2 atm and 26 Wat 4.5 atm, which are considerably 
higher than the values determined using Equation 2. This 
overprediction is expected, since Equation 4 assumes 100% 
efficient conversion of electrical energy by the transducer into 
acoustic energy. In contrast, Equation 2 yields an underpre-
diction, since perfect insulation of the apparatus is assumed. 
Thus, Equations 2 and 4 provide upper and lower bounds for 
the acoustic energy. 
Post-exposure Analysis 
The peak incident pressure generated within the exposure 
35 
chamber was estimated by measuring the acoustic pressure at 
subcaviation levels and linearly extrapolating to higher drive 
levels (Matula, et al., J. Acoust. Soc. Am. 101: 1994-2002) 
(1997)). At supra-cavitation levels, the incident pressure con-
tinuation to increase as a line function of the voltage, whereas 
40 
the measured pressured levels off and may decrease due to 
cavitation. A Linear fit of the data was therefore generated 
only at low pressure. (i.e. less than 2.0 atm. for degassed 
water) for the pressure as a function of transducer voltage: After exposure to ultrasound, samples were removed from 
45 the sample tube and spun down, as described above. The 
P~0.0089· V (r2~0.99) 
(l) supernatant contained free hemoglobin released from perme-
where peak positive pressure (P) has units ofatmospheres and abilized cells, while the pellet contained intact cells. The 
peak-to-peak voltage (V) has units of volts. This equation was supernatant was collected and the absorbance of hemoglobin 
extrapolated to higher voltages and pressures and was used to in the supernatant was determined at 575 nm using a spectro-
convert measured transducer voltages to the incident pres- 50 photometer (DU-64, Beckman Instruments). As a positive 
sures described in these examples. control, the absorbance was also determined for a sample in 
Measurement of Ultrasound Power and Heating which all cells were lysed by suspension in deionized water. 
Bulk heating caused by ultrasound was measured and The ratio of these absorbances yielded the percent hemoglo-
determined to be less than 1° C. for all exposures. Using an bin released, expressed as percent membrane permeabiliza-
iron/constant thermocouple (Model SAl-J thermocouple; 55 tion in the Figures described herein. 
Model DP 460 display; Omega Engineering, Stamford, Ct.) Results 
inserted into the water bath, which was mixed using a stir bar To develop a rational approach to designing protocols for 
and magnetic stirrer (VWR), the temperature was detemined ultrasound-mediated cell membrane permeabilization, the 
to rise at 0.17° C./min. during continuous exposure to ultra- degree of permeabilization of bovine red blood cells exposed 
sound at 2.2 atm. and at 0.73° C./min. at 4.5 atm incident 60 to low-frequency (24 kHz) ultrasound was measured as a 
pressure. 
Although incident pressure, rather than power, is used to 
characterize the strength of ultrasound, it should be helpful to 
know the power of ultrasound exposures used here for com-
parison with other studies. Assuming that all acoustic energy 
from the transducer was eventually converted into heat and 
that heat loss from the apparatus to the surroundings was 
function of incident ultrasound pressure, total exposure time, 
pulse length, and duty cycle. In addition, the amount of per-
meabilization was correlated with measurable acoustic sig-
nal, which is of interest to non-invasive monitoring ofultra-
65 sound's bioeffects and elucidation of mechanisms. The 
degree ofpermeailization was measured by release of hemo-
globin from erythrocytes. 
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cant, peakat3 msec. forboth2.7 atm. and8.9 atm. (p<0.05 by 
Student's T-test, relative to average permeabilization at pulse 
length ~0.1 sec). For each pressure tested, the degree of 
membrane permeabilization varied little as a function of pulse 
length. There was, however, a small statistically significant 
peak in permeabilization at 3 msec. A possible physical 
explanation for this peak is discussed below. 
FIG. la shows that permeabilization increased with 
increasing incident pressure (f=24 kHz), a measure of the 
total ultrasound exposure which cannot be measured directly 
in the presence of cavitation. Permeabilization exhibited an 
almost linear dependence for pressures greater than -0.5 atm, 
which is consistent with previous studies which show that 
bioeffects increase with ultrasound pressure or intensity 
(Stewart & Stratmeyer, eds., An Overview of Ultrasound: 
Theory, Measurement, Medical Applications, and Biological 
Effects (FDA 82-8190), U.S. Department of Health and 
Human Services (Rockville, Md. 1983); Suslick, ed., Ultra-
sound: Its Chemical, Physical, and Biological Effects (VCH, 
Deerfield Beach. Fla. 1988); Barnett, et al., Ultrasound Med. 
Biol. 20: 205-18 1994) ). Exposure Criteria for Medical Diag-
nostic Ultrasound: I. Criteria Based on Thermal Mechanims 
(NCRP Report No. 113) (Bethesda, Md. 1992)). FIG. lb 
shows that permeabilization increased with increasing sub-
harmonic pressure (f/2=12 kHz), a measure of cavitation 
which can be measured directly. These figures indicate that 
membrane permeabilzation is mediated by cavitation and that 
measurement of subharmonic pressure may be a noninvasive 
way to determine the degree of permeabilization (and thereby 
the amount of drug delivery) resulting from ultrasound expo-
sure. 
For pulsed ultrasound, the effect of duty cycle (defined as 
the fraction of time that the ultrsound is "on" during pulsed 
10 application) is shown in FIG. 5. Under the conditions inves-
tigated, duty cycle had no significant effect on the degree of 
membrane permeabilization. 
FIG. lb shows that Pf72 is predictive of the degree ofmem-
15 brane permeabilazation from exposures of different incident 
pressure, all having the same pulse length, exposure time, and 
duty cycle. To generalize the approach and consider expo-
sures of different pulse lengths, exposure times, duty cycles 
and incident pressures, membrane permeabilization was cor-
20 related with the total exposure time (t), which is equal to the 
product of pulse length and the number of pulses applied, 
multiplied by the strength of the f/2 signal (P f72 ). As shown is 
FIG. 6, this parameter (i:·Pf72 ) correlated well with membrane 
permeabilization, showing a threshold value at approxi-
FIG. 2 shows a representative spectrum of acoustic signals 
associated with an ultrasound exposure which causes exten-
sive cavitation. A strong signal is seen at the driving fre-
quency, f(i.e. 24 kHz), which is the frequency at which the 
transducer resonates. Due to cavitation and other effects, 
there are also strong signals at integer multiples of the driving 
frequency (e.g. 2f, 3f and 4f) and at the subharmonic fre-
quency, f/2, and its ultraharmonics (e.g., 3f/2, 5f/2, and 7f/2). 
The broadband noise pressure between these peaks (e.g. bl 
and b2) also is elevated. 
25 mately 0.01 (i.e., log(i:·Pf72)=-2). Below this threshold little 
permeabilization occurred, and above it permeabilization 
increased sharply. Because FIG. 6 includes all of the data 
collected in this study and because the parameter i:·Pf72 cor-
relates well with the whole data set, it appears that measure-
30 ment of this single parameter can provide a simple, non-
incasive, and broadly-applicable method for determining 
membrane permeabilization caused by any acoustic energy 
It was assessed whether cell membrane permeabilzation 35 
correlates with any of these features of the acoustic spectrum, 
as summarized in Table 1. The correlation was strongest for 
Pf72 (i.e., the pressure at f/2) and its ultraharmonics (set 2). 
FIG. lb shows this relationshilp graphically. Permeabiltiza-
tion also correlated with average measurements of broadband 40 
noise pressure between the peaks (set 3). The driving fre-
quency itself and its higher harmonics (set 1) showed the 
weakest correlation. Previous studies have correlated cell 
damage with Pf72 (Jeffers, et al., J. Acoust. Soc. Am. 97: 669-
76 (1995)) and 20 f(Everbach, et al., Ultrasound Med. Biol. 45 
23: 619-24 (1997)). Mechanistic interpretation of these 
results is provided below. These correlations may provide a 
useful means for noninvasively measuring cell permeabiliza-
tion by ultrasound. 
The effect of total exposure time of a single continuous 50 
ultrasound exposure is shown in FIG. 3. In each case, perme-
abilization increased with exposure time above a threshold of 
approximately 100 msec. Below approximately 100 msec, 
ultrasound had little effect on the cells. For longer exposure 
time. This is in qualitative agreement with previous studies 55 
conducted under somewhat different conditions, which also 
show that membrane disruption increases with exposure time 
above a threshold (Kober, et al., J. Acoust. Soc. Am. 86: 6-7 
(1989); Brayman, et al., Ultrasound Med. Biol. 22: 927-38 
(1996)). 60 
In FIG. 4, cells were exposed to ultrasound using pulses of 
different length, but the cumulative "on" time for each set of 
pulses was kept constant at 10 sec by varying the total number 
of pulses. Pulses were applied at a duty cycle of 10% and at 
three different incident pressures: ( +) 0.89 atm., (•) 2.7 atm., 65 
and (_..) 8.9 atm. Permeabilization showed a weak depen-
dence on pulse length, with a small, but statistically signifi-
exposure. 
The parameter i:·Pf72 was chosen because it characterizes 
the total cavitational exposure by accounting for both the 
strength of the f/2 cavitation signal (Pf72 ) and the time over 
which it acts (i:). The good correlation between permeabili-
zation and i:·Pf72 is significant because measuremaent of this 
single parameter can provide a simple, non-invasive method 
for determining membrane permeabilization caused by any 
ultrasound exposure. 
These studies showed that permeabilization increased with 
incident ultrasound pressure, increased with total exposure 
time above a threshold of approximately 100 msec, showed a 
weak dependence on pulse length with a small maximum at 3 
msec, and did not depend on duty cycle under the conditions 
examined. Using measured acoustic spectra, it was found that 
red blood cell membrane permeabilization correlated best 
with the pressure measured at half the driving frequency 
(f/2=12 kHz) and its ultraharmonics, less strongly with the 
broadband noise pressure measured between peaks, and least 
strongly with pressure measured at the driving frequency and 
its higher harmonics. Permeabilization caused by ultrasound 
applied at any set of conditions tested in this study could be 
well predicted by the parameter i:·Pf72 , which characterizes 
the total cavitational exposure. 
Discussion 
Effect of Ultrasound Parameters 
This study shows that permeabilization increases as a 
strong function of incident pressure (FIG. 1) and total expo-
sure time (FIG. 3), which indicates that selection of appro-
priate pressure and duration of ultrasound exposure is impor-
tant to achieve permeabilization at a desired level. The 
existence of a threshold near 100 msec of total exposure time 
(FIG. 3) also constrains possible protocols. In contrast, the 
observation that permeabilization depends only weakly on 
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pulse length (FIG. 4) and duty cycle (FIG. 5) is useful, since 
it permits greater flexibility in designing ultrasound proto-
cols. 
The effects of different ultrasound parameters summarized 
above can be explained in terms of cavitation, the mechanism 
14 
cavitation, "noise" over a broad spectrum of frequencies is 
given off, which raises peak and broadband signals alike 
(Leighton, The Acoustic Bubble (1994)). Since both f/2 and 
broadband signals showed correlation, it appears that both 
stable and transient cavitation play a role in membrane per-
meabilization. 
Finally, signals at f and its higher harmionics showed the 
poorest correlation (set 1 in Table 1 ). This was expected since 
these signals are related to the non-cavitaional driving fre-
quency (f) and resonance of the experimental apparatus 
(higher harmonics), in addition to stable and transient cavi-
tation. The signal f and its higher harmonics are not expected 
to be good indicators, since it reflects a mixture of effects. 
by which membranes are believed to be disrupted (Barnett, et 
al., Ultrasound Med. Biol. 20: 205-18 (1994); Leighton, The 
Acoustic Bubble (Academic Press, London 1994)). It is well 
established that at greater acoustic pressure more cavitation 
bubbles with greater energy are created (Leighton, The 10 
Acoustic Bubble (1994)). Similarly, longer total exposure 
times also yield more cavitation bubbles. This increased cavi-
tation should result in more extensive membrane permeabi-
lization, as seeninFIG. l and3. The minimum exposure time 
ofl 00 msec shown in FIG. 3 could result from the "warm-up" 
time it takes for bubbles to nucleate, grow, and possibly 
collapse over many ultrasound cycles (Margulis, Sov. Phys. 
Acoust. 22: 145-47 (1976)). 
15 Conclusion 
The maximum permeabilization observed for 3 msec 
pulses in FIG. 4 could be explained by two competing effects 20 
involving a mechanism proposed previously (Ciaravino, et 
al., Ultrasound Med. Biol. 7: 159-66 (1981 )). Increasing 
pulse length is advantegeous for caviation because there is 
more time during each pulse for bubbles to nucleate, grow and 
collapse. However, it is believed that as pulse length increases 25 
so does the time between pulses at constant duty cycle, which 
means that as the interpulse delay increases bubbles formed 
during the previous pulse have time to dissolve back into 
solution. This mechanism is disadvantageous because it 
leaves fewer nucleation bubbles available to grow and col- 30 
lapse during the next pulse, which results in less cavitiation. 
Correlation with Measured Acoustic Signals 
Ultrasound causes cavitation which in tum causes effects 
on cells. Therefore the most useful predictor of ultrasound's 
effects on cells should be a measure of cavitation. Membrane 35 
permeabilization was correlated with measured acoustic sig-
nals which are known to be associated with cavitation. A good 
correlation was found for the pressure measured at half the 
driving frequency (f/2=12 kHz) and its ultraharmonics (FIG. 
lb, set 2 of Table 1) In addition, permeabilization caused by 
ultrasound applied at any set of conditions tested in this study 
could be well predicted by the parameter i:·P1w which char-
acterizes the total cavitational exposure by accounting for 
both the strength of the f/2 cavitation signal and the time over 
which it acts. 
40 
45 
Correlation of acoustic signals with membrane permeabi-
lization also provides mechanistic insight. The best correla-
tion was found for the signal at f/2 and its ultraharmonics (set 
2 of Table 1, FIG. lb). This suggests that permeabilization 
was mediated by cavitation. Onset of the f/2 signals is thought 
to occur with the onset of cavitation (Leighton, The Acoustic 
Bubble (1994)). As the cavitation activity increases, the f/2 
signals also generally increase, but a quantitative relationship 
between amount of cavitation and Pf72 has not been estab-
lished. Cavitation bubbles are thought to give off a signal at 
f/2 because of a prolonged expansion phase and delayed 
collapse which can occur during cavitation (Leighton, The 
Acoustic Bubble (1994)). Measurement of f/2 signals at the 
exact frequency of interest (e.g. 12 kHz; set 2a) yielded a 
somewhat better correclation with permeabilization than 
measurement of the signal over the width of the peak (e.g., 
11-13 kHz; set 2b) 
A reasonable correlation also was established for measure-
ments of broadband signals, or the signals between f, f/2, and 
higher harmonics (set 3 of Table 1), which also supports a 
permeabilization mechanism involving cavitation, especially 





This study provides a quantitative guide to designing ultra-
sound protocols useful for drug delivery. The acoustic mea-
surements support the hypothesis that ultrasonic cavitation is 
the mechanism by which membranes are permeabilized. 
They also indicate that measurable acoustic signals can pro-
vide noninvasive real-time feedback about membrane perme-
abilization and drug delivery. 
Using red blood cells as a model system, it was shown that 
membrane permeabilization increases with incident ultra-
sound pressure, increases with total exposure time above a 
threshold of 100 msec, shows a weak dependence on pulse 
length with a small maximum at 3 msec, and does not depend 
on duty cycle under the condition examined. In addition, the 
degree of permeabilization was shown to correlate with mea-
surable acoustic signals (e.g. Pf72 , i:·Pf72 ), which supports the 
belief that permeabilization is mediated by cavitation and 
may provide a method for noninvasive, real-time feedback for 







Empirical Correlation of Membrane Permeabilization 
with Measured Acoustic Signals 
Frequency (kHz)" Correlated Equationb 
24 (ff M ~ 19.7 ln (P) + 30.6 
48 (2f) M ~ 12.4 ln (P) + 43.2 
72 (3f) M ~ 11.8 ln (P) + 49.2 
96 (4f) M ~ 11.4 ln (P) + 53.6 
23-25 (f) M ~ 19.7 ln (P) + 65.0 
47-49 (2f) M ~ 12.7 ln (P) + 64.8 
71-73 (3f) M ~ 12.3 ln (P) + 68.9 
95-97 (4f) M ~ 11.7 ln (P) + 69.4 
12 (f/2) M ~ 9.4 ln (P) + 73.0 
36 (3f/2) M ~ 8.5 ln (P) + 64.7 
60 (5f/2) M ~ 8.7 ln (P) + 64.4 
84 (7f/2) M ~ 9.6 ln (P) + 69.6 
11-13 (f/2) M ~ 10.1 ln (P) + 79.8 
35-37 (3f/2) M ~ 9.0 ln (P) + 70.8 
59-61 (5f/2) M ~ 9.3 ln (P) + 70.3 
83-85 (7f/2) M ~ 9.8 ln (P) + 73.1 
13-23 (bl) M ~ 10.2 ln (P) + 82.3 
25-35 (b2) M ~ 10.5 ln (P) + 82.9 
37-47 (b3) M ~ 10.2 ln (P) + 80.6 
49-59 (b4) M ~ 10.6 ln (P) + 78.2 
61-71 (b5) M ~ 10.3 ln (P) + 78.2 
73-83 (b6) M ~ 10.6 ln (P) + 79.7 

























aBased on spectral information such as that shown in FIG. 2, membrane permeabilization 
was correlated with the pressure (or the average pressure when a range of frequencies is 
§~~~~:~~~~~~;i~~;e~~1'£~~~;'~0~ I~~~~n~~;r~{~~~~~b~~~~c~~r~eabilization (M) and 
measured pressure (P) is shown. There is no mechanistic basis for the log-linear function-
ality; visual inspection suggested it was the most appropriate fit of the data. The units of 
permeabilization are percent hemoglobin released and the units of pressure are atrn. 
cThe r2 correlation coefficient is shown for each fit of the data. 
dThe text in parentheses refers to which harmonic of the driving frequency (f = 24 kHz) the 
indicated frequencies correspond and "b" indicates a broadband noise measurement. 
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sec. (for P=5.3 atm. and 10 ms pulses at 10% duty cycle), 
while cell viability decreased continuously. Average uptake 
showed a smalil maximum at 10-33 ms and a sharp decline at 
less than 3 ms, with changes in pulse length from 0.3 ms to 1.0 
s.Applied duty cycle (from 0.5% to 80%) did not significantly 
affect uptake. Fraction of viable cells decreased as uptake 
increased for most conditions, and was approximately 25% 
for maximum uptake under optimal conditions. 
Membrane disruptions were found to be large enough to 
The effects of ultrasound exposure on size, lifetime, and 
permeability of membrane disruptions in living cells were 
investigated quantitatively. It was found that ultrasound dis-
ruptions were a few nanometers in size, have a lifetime of 
approximately one minute, and induce extensive molecular 
uptake. 
Methods 
10 allow uptake of bovine serum albumen (radius, r approxi-
mately 3.5 nm). Average uptake of BSA molecules per 
exposed cell was about 60% less than that of calcein (r,.,0.7 
nm ), for the same external concentration (10 µM) and same 
Prostate tumor cells (DU-145) were suspended in RPMI-
1640 medium with 10% fetal bovine serum at 5xl05 cells/ml. 15 
exposure condtions as given in FIG. 7 (at P=8.0 atm.). 
To determine lifetimes of the membrane disruptions, cal-
cein was added to cell suspensions at different times after 
ultrasound exposure. As shown in FIG. 8, average uptake of 
calcein decreased exponentially with time at which calcein 
was added to a sample (~ 15 s after exposure). The data at the 
For each experimental condition, a 3 ml polypropylene tube 
was filled with the cell suspension at room temperature 
(22±2° C.) and the top of the tube was closed without entrap-
ping any air bubbles. The cells were exposed to ultrasound at 
24 kHz in a chamber that consisted ofa cylindrical piezoelec-
tric transducer sandwiched between two PVC pipes and filled 
with deionized and degassed water at room temperature. 
Pressure, pulse length, duty cycle, and the total exposure time 
of ultrasound exposure were controlled. Acoustic spectra dur-
ing exposure were collected using a hydrophone placed in the 
exposure chamber. Calcein, a green-fluorescent membrane-
impermeant marker, dissolved in saline, was added to the 
suspensions either before or at various times after exposure at 
20 incident pressures, 5.3 atm. (o ), 7.1 atm. (•) and8.0 atm. (_..), 
were fitted with exponentially functions, and shown in FIG. 8. 
The respective time decay constants, i:, at these pressures 
were 78 sec., 66 sec, and 56 sec., respectively. One can see 
that the time decay constant, i:, decreased and the initial 
25 uptake increased with increasing incident pressure. Average 
uptake was about 50% less when calcein was added 15 sec. 
after exposure compared to when it was added before expo-
sure for the examined pressures. However, significant uptake 
a final concentration of 10 µM. Other fluorescent markers, 
with different sizes, were also used to deterimine membrane 30 
permeability. The cells were kept at room temperature for 15 
minutes after exposure, and then placed on ice until they were 
centrifuged add resuspended in phosphate-buffered saline 
with 0.1 mg/ml of propidium iodide (a red-fluorescence via-
blity stain). Cell-by-cell fluorescence was measured using 35 
flow cytometry and 6 µm green-fluorescence microspheres 
were added to each sample at a constraint concentration to 
provide an internal volumetric standard for determining con-
centrations of viable cells. 
Results and Discussion 40 
To better understand how cells are permeabilized by ultra-
sound, potential mechanisms of membrane disruptions were 
tested. First, it was observed that cells were permeabilized 
only in presence of extensive cavitation, as indicated by char-
acteristic changes in measured acoustic spectra (i.e., strong 45 
subharmonic and ultraharmonic peaks and broadband noise). 
Other effects of ultrasound, such as bulk heating and mixing 
were ruled out as potential mechanism, since control experi-
ments of heating (up to 2° C., the maximum temperature rise 
in these experiments) and mixing had negligible effects on 50 
cells. Also, cavitation-induced free radicals probably are not 
responsible, because membrane permeabilization was 
observed in the presence of free radical scavengers (e.g., 50 
µM cystearmine ). Therefore, micro scale hydrodynamic 
effects of cavitation probably are the main factor in disrupting 55 
cell membranes. 
The effects of ultrasound exposure parameters on cell 
viability and membrane permeabilization (as measured by 
uptake of calcein added to the cell suspension before expo-
sure) were determined to identify conditions that selectively 60 
pereabilize cells without killing them. As peak incident pres-
sure increased, average cellular calcein uptake increased 
above a threshold and reached a plateau at 20-25% of external 
calcein concentration (FIG. 7). However, the function of 
viable cells (relative to an unexposed suspension) decreased 65 
continuously with increasing pressure (FIG. 7). Uptake 
increased with total exposure time and reached a plateau at 5 
occurred for up to two minutes after exposure. 
Modifications add variations of the present invention will 
be obvious to those of skill in the art from the foregoing 
detailed description. Such modifications and variations are 
intended to come wthin the scope of the following claims. 
We claim: 
1. A method for altering permeability of tissues or cells 
comprising 
(a) administering acoustic energy at a driving frequency by 
applying a transducer to a first site on a human or other 
animal, 
wherein the first site is selected from the group consisting 
of skin, cornea, conjunctiva, sclera, mucosa of the nose, 
mucosa of the mouth, mucosa of the rectum and mucosa 
of the vagina, 
wherein the acoustic energy is effective to increase perme-
ability of tissues or cells at a second site distant from the 
first site, wherein the second site is not skin, cornea, 
conjunctiva, sclera, mucosa of the nose, mucosa of the 
mouth, mucosa of the rectum or mucosa of the vagina, 
and 
wherein the acoustic energy does not alter permeability, 
cell viability or structural integrity at the first site, 
(b) measuring the effect on the second site of the acoustic 
energy or a property of the acoustic energy at the time of 
or subsequent to the initial application of the acoustic 
energy, 
wherein the effect on the second site or the property of the 
acoustic energy is measured at (i) one or more frequen-
cies other than the driving frequency at which the acous-
tic energy is applied, wherein the one or more frequen-
cies correspond to integer multiples of one-half or one-
fourth of the driving frequency, or 
(ii) one or more frequencies taken from a broadband signal 
at a frequency greater than the driving frequency, and 
( c) using the measurement obtained in step (b) to modify 
continued or subsequent application of acoustic energy 
from the transducer at the first site. 
US 7,972,286 B2 
17 
2. The method of claim 1 wherein the property of the 
acoustic energy being measured in step b is one or more 
properties selected from the group consisting of pressure, 
energy input, and length of time the acoustic energy is admin-
istered. 
3. The method of claim 1 wherein the increased permeabil-
ity is partially or completely reversible. 
4. The method of claim 1 wherein the second site is a 
biological membrane. 
5. The method of claim 1 wherein the acoustic energy is 
applied in an amount effective to disaggregate or dissociate 
cells or tissue in the second site. 
6. The method of claim 1 wherein the second site comprises 
blood vessels. 
7. The method of claim 1 wherein the acoustic energy is 
applied at a frequency between 1 kHz and 10 MHz. 
8. The method of claim 1 wherein the acoustic energy is 
ultrasound. 
9. The method of claim 1 wherein the acoustic energy is 
applied at a peak positive pressure of up to 100 atmospheres. 
10. The method of claim 1 wherein the application of 
acoustic energy causes cavitation within or on the surface of 
the second site. 
18 
parameter selected from the group consisting of temperature, 
fluid gas content, administration rate of molecules to be trans-
ported, sample collection rate, device position, and combina-
tions thereof. 
16. The method of claim 1 wherein the application of the 
acoustic energy is modified by interrupting the application. 
17. The method of claim 1 wherein the second site com-
prises a tumor. 
18. The method of claim 1 wherein the acoustic energy 
10 alters transport of molecules selected from the group consist-
ing of therapeutic, prophylactic and diagnostic agents. 
19. The method of claim 1, wherein the second site is 
selected from the group consisting of the gastrointestinal 
tract, pulmonary mucosa, blood and lymphatic vessel walls, 
15 internal organs, tumors, and bones. 
20. The method of claim 1 wherein the acoustic energy is 
effective to increase permeability of the second site to a 
chemical or biological agent selected from the group consist-
ing of peptides, proteins, sugars, polysaccharides, nucle-
20 otides, polynucleotide molecules, synthetic organic com-
pounds, synthetic inorganic compounds, and combinations 
and aggregates thereof. 
11. The method of claim 1 further comprising administer-
ing an agent to the second site to alter permeability of the 25 
second site. 
21. The method of claim 20 wherein the chemical or bio-
logical agent is delivered to cells or tissue at the second site. 
22. The method of claim 21 wherein the chemical or bio-
logical agent is in a form selected from the group consisting of 
cells or virus particles, nano or microparticles, liposomes or 
other lipid vesicles or emulsions. 
23. The method of claim 21 wherein the chemical or bio-
12. The method of claim 1 wherein the property of the 
acoustic energy is measured at a frequency or frequencies 
corresponding to integer multiples of one-half or one-fourth 
of the driving frequency. 
13. The method of claim 1 wherein the acoustic energy 
measurement is analyzed using a mathematical algorithm 
selected from the group consisting of Fourier Transform and 
the Fast Fourier Transform. 
30 logical agent is detected or quantitated, further comprising 
removing biological fluid or molecules simultaneously, 
previously, or subsequently to the application of acous-
tic energy, and 
14. The method of claim 1 wherein the application of the 35 
acoustic energy is modified by changing an acoustic param-
eter selected from the group consisting of pressure, energy, 
frequency, pulse length, total exposure time, duty cycle, and 
combinations thereof. 
15. The method of claim 1 wherein the application of the 40 
acoustic energy is modified by changing a non-acoustic 
assaying the biological fluid or molecules to detect or 
quantitate the chemical or biological agent. 
24. The method of claim 1 wherein the property of the 
acoustic energy is measured at one or more frequencies taken 
from the broadband signal at frequencies greater than the 
driving frequency. 
* * * * * 
